Bombesin

A tetradecapeptide originally obtained from the skins of toads Bombina bombina and B. variegata. It is also an endogenous neurotransmitter in many animals including mammals. Bombesin affects vascular and other smooth muscle, gastric secretion, and renal circulation and function.

Also Known As:

Networked: 1127 relevant articles (48 outcomes, 150 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Schally, Andrew V: 33 articles (05/2014 - 03/2002)
2.	Reubi, Jean Claude: 18 articles (03/2019 - 04/2002)
3.	Halmos, Gabor: 16 articles (10/2012 - 10/2003)
4.	Chen, Xiaoyuan: 15 articles (01/2018 - 08/2004)
5.	Jensen, Robert T: 14 articles (01/2021 - 06/2002)
6.	Waser, Beatrice: 14 articles (03/2019 - 07/2002)
7.	Schally, A V: 14 articles (05/2008 - 03/2000)
8.	Smith, Charles J: 13 articles (07/2018 - 03/2005)
9.	Rogers, Buck E: 12 articles (06/2022 - 07/2003)
10.	Moody, Terry W: 12 articles (01/2021 - 01/2003)

Related Diseases

1.	Neoplasms (Cancer) 12/15/1997 - "The biodistribution study showed that the tumor localization (14.9 +/- 8.2% injected dose/gram; ID/g) of [125I]-mIP-bombesin 2 days after administration of AdCMVGRPr was significantly greater than its localization in other organs (P < 0.003) and was significantly greater than in AcCMVLacZ- and saline-treated mice (P < 0.003). " 08/01/1997 - "Additionally, tumors transduced in vivo to express GRPr demonstrated significantly greater localization of [125I]-mIP-bombesin when compared with [125I]-Tyr4-bombesin." 01/01/2019 - "Bombesin (Bn) receptors have shown great promise for tumor targeting due to their increased expression in a variety of human cancers, including prostate, breast, small cell lung, and pancreatic cells. " 01/01/2011 - "In contrast, conjugation to a bombesin analog lacking the receptor-binding domain failed to increase the cytotoxicity of MG2, suggesting that bombesin conjugation enhances the cytotoxicity of MG2 in cancer cells through improved binding. " 04/05/2010 - "Bombesin and its analogues show promise for the targeted delivery of radioactive and chemotherapeutic agents to a wide variety of solid tumors. "
2.	Prostatic Neoplasms (Prostate Cancer) 05/06/2013 - "Preclinical evaluation of a novel ¹¹¹In-labeled bombesin homodimer for improved imaging of GRPR-positive prostate cancer." 07/01/2010 - "A standardised study to compare prostate cancer targeting efficacy of five radiolabelled bombesin analogues." 11/01/2020 - "A comparative PET imaging study of 44gSc- and 68Ga-labeled bombesin antagonist BBN2 derivatives in breast and prostate cancer models." 04/04/2016 - "In this study, we have evaluated a novel (68)Ga-labeled bombesin derivative for PET imaging of prostate cancer in vivo. " 03/01/2015 - "The aim of this first-in-man study was to demonstrate the feasibility, safety, and tolerability, as well as provide dosimetric data and evaluate the imaging properties, of the bombesin analogue BAY 864367 for PET/CT in a small group of patients with primary and recurrent prostate cancer (PCa). "
3.	Adenocarcinoma 02/01/2014 - "There was a significant GRP receptor density gradient (P ≤ 0.005), increasing from normal prostate glands (mean relative optical density, ROD, of ¹²⁵I-Tyr⁴ -bombesin binding: 0.17) over atypical glands without increased MIB-1 labeling (0.28) and atypical glands with increased MIB-1 expression (0.44) to high grade PIN and adenocarcinoma (0.64 and 0.58, respectively). " 07/01/2006 - "We hypothesized that pancreatic ductal adenocarcinoma (PDAC) might be imaged with the inverse strategy, that is by the design of a nanoparticle-conjugate targeted to bombesin (BN) receptors present on normal acinar cells of the pancreas. " 04/01/2006 - "Comparative in vitro and in vivo evaluation of two 64Cu-labeled bombesin analogs in a mouse model of human prostate adenocarcinoma." 09/01/1994 - "Bombesin inhibits growth of pancreatic ductal adenocarcinoma (H2T) in nude mice." 01/01/1988 - "We studied the effects of chronic bombesin treatment on the growth of a human ductal pancreatic adenocarcinoma (SKI) xenografted into nude mice, and on the growth of the normal nude mouse pancreas. "
4.	Neoplasm Metastasis (Metastasis) 03/01/1991 - "The presence of both CRH and bombesin was documented by immunocytologic studies in the metastases (lymph node and suprasellar biopsy). " 03/01/1991 - "Because of the close proximity of the suprasellar metastasis to the portal pituitary circulation, CRH and bombesin could have been readily provided to the pituitary corticotrophs." 01/01/1985 - "Very high concentrations of bombesin were identified in these metastases." 11/01/2001 - "Increased bombesin expression was correlated with colorectal adenocarcinomas exhibiting poor histological grade and their liver metastases. " 01/01/2001 - "Bombesin significantly increased the incidence of intestinal tumors and cancer metastasis to the peritoneum. "
5.	Duodenal Ulcer (Curling's Ulcer) 11/01/1985 - "Bombesin and G-17 dose responses in duodenal ulcer and controls." 03/01/1983 - "An increased parietal cell mass could explain the higher gastric acid response after bombesin infusion in our group of patients with duodenal ulcer." 01/01/1979 - "Bombesin was found to be a very potent stimulator of gastric acid secretion in patients with duodenal ulcer. " 11/01/1985 - "Serum gastrin with bombesin stimulation was significantly greater in duodenal ulcer (maximum 467 pg/ml) than in controls (153 pg/ml), while in seven of the DU group tested gastrin levels after a meal were not different from that seen in five of the normal controls. " 03/01/1993 - "The total net increase of somatostatin in the presence of bombesin was significantly less in duodenal ulcer patients (0.10 +/- 0.02 ng/mg wet w.) than in normal subjects (1.45 +/- 0.24 ng/mg wet w.) (p < 0.01). "

Related Drugs and Biologics

1.	Bombesin Receptors (Bombesin Receptor)
2.	Somatostatin (Somatotropin Release-Inhibiting Factor)
3.	Gastrins
4.	Gastrin-Releasing Peptide
5.	Peptides (Polypeptides)
6.	Substance P
7.	Tpi(6)-Leu(13)-psi(CH2NH)-Leu(14)- bombesin (6-14)
8.	Androgens
9.	Adrenocorticotropic Hormone (ACTH)
10.	Cholecystokinin (Pancreozymin)

Related Therapies and Procedures

1.	Radiotherapy
2.	Therapeutics
3.	Intravenous Administration
4.	Intravenous Injections
5.	Drug Therapy (Chemotherapy)